Here's what we'll cover
Here's what we'll cover
Why Medicare Prescriptions for Wegovy Are Surging
If you've heard that Medicare is now covering Wegovy for certain patients and wondered whether that applies to you, you're not alone. Prescriptions among Medicare beneficiaries have climbed substantially since the coverage expansion took hold, and millions of older Americans are now asking the same question: do I qualify?
The short answer is that it depends on your medical history. Medicare's coverage of Wegovy (semaglutide 2.4 mg) for cardiovascular risk reduction is a significant policy shift, but it comes with specific eligibility requirements. Understanding those requirements, and knowing what they mean for your costs and care, is the most practical place to start.
What Changed and Why It Matters
For years, Medicare was legally restricted from covering weight loss medications. The law considered obesity drugs a "lifestyle" benefit, and they were explicitly excluded from Part D coverage.
That began to change when the SELECT trial, a large cardiovascular outcomes study involving over 17,000 adults, found that semaglutide reduced major cardiovascular events (heart attacks, strokes, and cardiovascular death) by 20 percent in people with obesity or overweight who already had established heart disease. This was the evidence the FDA and CMS (Centers for Medicare and Medicaid Services) needed.
The FDA approved Wegovy for cardiovascular risk reduction in March 2024. CMS then clarified that Medicare Part D plans could cover it specifically under this cardiovascular indication. That opened the door for a coverage category that didn't exist before.
Who Qualifies for Medicare Coverage of Wegovy
This is where the details matter most. Medicare coverage for Wegovy under the cardiovascular indication is not automatic for everyone with obesity. You generally need to meet all of the following criteria:
- Established cardiovascular disease, meaning a documented history of a heart attack, stroke, peripheral artery disease, or similar condition. Being at risk for heart disease without a prior event typically does not qualify on its own.
- BMI of 27 or higher, since the SELECT trial that supported this indication enrolled adults at that threshold and coverage is generally tied to it.
- Medicare Part D enrollment, since coverage comes through Part D prescription drug plans rather than Medicare Parts A or B, and your specific plan's formulary will determine your cost-sharing.
If you have obesity but no cardiovascular history, the standard coverage rules still apply, and Wegovy remains excluded from most Medicare plans for weight management alone. However, this is an evolving area of policy, so checking with your plan and your doctor is always worthwhile.
What You Can Expect to Pay
Even with Medicare coverage, Wegovy is not free. Your actual out-of-pocket cost depends on which Part D plan you have, what tier Wegovy falls on in that plan's formulary, and where you are in the Medicare benefit structure for the year.
Here's a general breakdown of how cost-sharing might look:
The Inflation Reduction Act's $2,000 annual out-of-pocket cap for Part D enrollees, effective in 2025, is genuinely significant here. Wegovy's list price is over $1,300 per month, so hitting the catastrophic cap could limit your annual exposure meaningfully compared to paying full price.
Still, costs in the initial and deductible phases can be substantial. Comparing Part D plans during open enrollment with Wegovy's coverage and tier in mind is one of the most practical steps you can take.
How to Talk to Your Doctor About This
If you think you qualify, the next step is a direct conversation with your prescribing physician or cardiologist. Don't assume your doctor will automatically know your Medicare plan covers Wegovy, or that they'll bring it up unprompted.
Here are specific questions worth raising:
- Do I have an established cardiovascular diagnosis that would support a Wegovy prescription for cardiovascular risk reduction, since the indication and how the prescription is coded directly affects whether insurance will process the claim?
- Can you document my cardiovascular history in a way that supports a prior authorization if my plan requires one, since strong clinical documentation significantly improves approval rates?
- Are there other GLP-1 options that might be covered differently under my plan, since Ozempic and Mounjaro have different indications and formulary positions that could affect my out-of-pocket cost?
Bring a printed summary of your Part D plan's formulary to the appointment if you can. It makes the conversation much more concrete.
Prior Authorization: The Obstacle Most Patients Don't Expect
One reason many Medicare patients with qualifying conditions still aren't on Wegovy is prior authorization, the process where your insurance plan reviews whether the medication is medically necessary before approving coverage.
Even with the cardiovascular indication in place, most Part D plans require prior authorization for Wegovy. That means your doctor needs to submit documentation, your plan reviews it, and approval can take days to weeks. Some requests are denied initially and require an appeal.
If your initial prior authorization is denied, don't give up. You have the right to appeal, and appeals that include strong clinical documentation (including evidence of your cardiovascular history and any other treatments you've tried) succeed more often than many patients expect.
Your doctor's office should be able to manage this process, but it helps to follow up proactively and ask for status updates.
What If You Don't Have Cardiovascular Disease?
If you're on Medicare but don't have established cardiovascular disease, you're not without options. You just need a different strategy.
For patients with type 2 diabetes, Ozempic (semaglutide 1 mg) and Mounjaro (tirzepatide) are prescribed for blood sugar management and are generally covered under Medicare Part D when the diabetes indication is supported. These medications also produce significant weight loss as a secondary effect in many patients.
For patients without diabetes or cardiovascular disease, Medicare coverage of GLP-1s for weight management alone remains very limited. In these cases, exploring manufacturer savings programs, GLP-1 coupons, or telehealth providers that specialize in GLP-1 access may be your best path forward. Comparing top GLP-1 providers can help you identify programs with transparent pricing and clinical support.
The Bigger Picture: Why This Coverage Shift Matters
The surge in Medicare prescriptions for Wegovy is not just a billing trend. It reflects a broader shift in how cardiovascular care is being delivered to older Americans.
Semaglutide is the first obesity-related medication to demonstrate a reduction in actual cardiovascular events in a major outcomes trial. That puts it in a different category from previous weight loss drugs, which were evaluated primarily on weight outcomes. Cardiologists, internists, and endocrinologists are increasingly treating semaglutide as a cardiovascular medication that happens to cause weight loss, not the other way around.
This framing has practical implications for you as a patient. If your primary concern is heart health rather than weight, framing the conversation with your doctor through that lens may help with both the clinical rationale and the insurance justification.
No waiting list. No insurance needed.
Frequently Asked Questions
Does Medicare cover Wegovy for weight loss?
Not for weight loss alone. Medicare Part D can cover Wegovy specifically for cardiovascular risk reduction in patients with established heart disease and a BMI of 27 or higher. Coverage for obesity management without a cardiovascular or diabetes indication remains largely excluded under current Medicare law.
What is the out-of-pocket cost for Wegovy on Medicare?
Costs vary by plan and coverage phase, but the 2025 Inflation Reduction Act cap limits annual Part D out-of-pocket spending to $2,000. Before reaching that cap, you may pay a deductible plus 20-33% coinsurance depending on what tier your plan places Wegovy on.
What cardiovascular conditions qualify for Medicare Wegovy coverage?
Qualifying conditions generally include a documented history of heart attack, stroke, angina with confirmed coronary artery disease, or peripheral artery disease. Being at high cardiovascular risk without a confirmed event or diagnosis typically does not qualify under the current indication.
How do I get my Medicare plan to approve Wegovy?
Most Part D plans require prior authorization. Your doctor must submit documentation of your cardiovascular diagnosis, your BMI, and the clinical rationale. If your initial request is denied, you have the right to file an appeal, which often requires additional documentation from your physician.
Is semaglutide covered under Medicare if I have diabetes?
Yes. Ozempic (semaglutide 1 mg), which is approved for type 2 diabetes, is generally covered under Medicare Part D when prescribed for blood sugar management. This is a separate indication from Wegovy and has different coverage rules.
Can I use a GLP-1 coupon or savings card with Medicare?
Federal law generally prohibits Medicare beneficiaries from using manufacturer copay cards or coupons for drugs covered by Medicare. If Wegovy is covered under your Part D plan, those savings programs do not apply. However, if you are paying entirely out of pocket and not billing Medicare, you may be able to use other savings options. Ask your pharmacist to clarify your situation.
The Bottom Line: What This Coverage Expansion Means for You
The spike in Medicare prescriptions for Wegovy is a meaningful signal, but it doesn't automatically mean you're covered or that the process will be simple.
If you have established cardiovascular disease and a BMI of 27 or higher, you likely meet the clinical criteria. The next step is working with your doctor to confirm your diagnosis is clearly documented, prepare for a prior authorization process, and review your specific Part D plan's formulary and cost-sharing structure.
If you don't have cardiovascular disease, your options are narrower under Medicare, but they're not zero. Ozempic and Mounjaro through the diabetes indication, telehealth programs with transparent pricing, and available GLP-1 savings resources are all worth exploring.
The most important step any reader can take right now is to have an informed conversation with their prescribing physician. Bring your Part D plan details, ask about prior authorization requirements, and make sure your medical records reflect the diagnoses that support coverage.
GLP-1.com is here to help you navigate the decisions that come before and after that conversation. Whether you're comparing Wegovy, Ozempic, or Mounjaro, or trying to figure out which GLP-1 provider fits your situation, our independent comparisons and resources are built to cut through the confusion.
Always consult your physician before starting, stopping, or changing any medication. Individual medical history, plan coverage, and clinical needs vary significantly.